We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
The current IMVT market cap is 4.19B. The company's latest EPS is USD -1.4520 and P/E is -19.86.
| Quarter End | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -64.03M | -64.26M | -78.48M | -61.8M | -61.55M |
| Net Income | -63.23M | -59.43M | -73.94M | -58.66M | -51.42M |
| Year End March 30 2023 | 2018 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Operating Income | 0 | -66.08M | -108.12M | -156.03M | -218.28M |
| Net Income | 0 | -66.39M | -107.43M | -156.73M | -210.96M |
| Quarter End | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 456.24M | 405.84M | 351.22M | 292.07M | 711.45M |
| Total Liabilities | 41.57M | 43.34M | 51.36M | 40.26M | 32.1M |
| Total Equity | 414.68M | 362.49M | 299.87M | 251.81M | 679.34M |
| Year End March 30 2023 | 2018 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 405k | 109.39M | 412.49M | 515.56M | 405.84M |
| Total Liabilities | 380k | 15.32M | 21.01M | 45.74M | 43.34M |
| Total Equity | 25k | 94.07M | 391.48M | 469.83M | 362.49M |
| Quarter End | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -132.4M | -188.19M | -47.37M | -107.43M | -154.53M |
| Investing | -171k | -197k | -45k | -79k | -210k |
| Financing | 70.65M | 70.89M | 890k | 1.04M | 470.88M |
| Year End March 30 2023 | 2018 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | N/A | -53.36M | -83.33M | -106.11M | -188.19M |
| Investing | N/A | -31k | -210k | -254k | -197k |
| Financing | 325k | 146.97M | 383.11M | 200.13M | 70.89M |
| Market Cap | 4.19B |
| Price to Earnings Ratio | -19.86 |
| Price to Sales Ratio | 0 |
| Price to Cash Ratio | 11.13 |
| Price to Book Ratio | 11.56 |
| Dividend Yield | - |
| Shares Outstanding | 145.29M |
| Average Volume (1 week) | 1.26M |
| Average Volume (1 Month) | 1.12M |
| 52 Week Change | 58.92% |
| 52 Week High | 45.58 |
| 52 Week Low | 17.53 |
| Spread (Intraday) | 35 (87.5%) |
| Company Name | Immunovant Inc |
| Address |
251 little falls drive wilmington, delaware 19808 |
| Website | https://www.immunovant.com |
| Industry | biological pds,ex diagnstics (2836) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
